Nijmegen, Netherlands

State of the Art Radionuclide Imaging and Therapy in Oncology

when 12 July 2021 - 16 July 2021
language English
duration 1 week
credits 2 EC
fee EUR 600

Radionuclides are important tools for imaging and therapeutic applications in oncology. When radionuclides are combined with tumor-targeting molecules (tracers), they can be used to non-invasively visualize tumor lesions. A well-known example is positron emission tomography (PET) with 18F-fluorodeoxyglucose ([18F]FDG). With recent developments of novel biologics for therapy in oncology, more advanced radio-imaging techniques have become available. For instance, radiolabeled tracers can be used to identify patients who could benefit from the latest immunotherapies, or can be used for treatment response monitoring. In addition to imaging, tracers can also be coupled to therapeutic radionuclides (e.g. alpha- or beta-emitters) which can be used to specifically irradiate tumor lesions while preventing exposure to healthy tissue.

During the course, the characteristics of different radionuclides (e.g. imaging and therapeutic radionuclides) and tumor targeting agents (e.g. antibodies, peptides, small molecules) will be discussed, as well as the latest radiochemical methods to label radionuclides to targeting molecules. Furthermore, the course provides you with both knowledge and hands-on experience with cell-based assays and in vivo evaluation of the tumor targeting and therapeutic efficacy of immunotherapy radiotracers. Examples are imaging of the PD-L1 checkpoint and in vivo T-cell imaging with antibodies, antibody fragments or by ex vivo cell labeling. You will learn to select the best in vitro experiment and how to set up and perform in vivo imaging and therapy experiments in several practical sessions. The final step, translation in to the clinic, will also be covered during the course, and examples will be provided of bringing imaging and therapeutic radionuclides into the clinic.

The course will contain lectures from several expert speakers, site-visits to research facilities, hands-on work with radiometals in cell assays and in vivo imaging experiments. Furthermore, we will organize meet-the-researchers sessions giving you the chance to have in-depth discussions on your topic of interest. The topics include alpha/beta emitters for radionuclide therapy, imaging in immuno-oncology, in vivo cell tracking and radiolabeling methods. In case your oncology research can benefit the use of radionuclides, this course will provide you with both basic knowledge and advanced insights in the exciting field of radionuclide imaging and therapy for oncology.

Course leader

Sandra Heskamp
Assistant professor
Medical Imaging
Radboud University Medical Center

René Raavé
Senior post-doc
Medical Imaging
Radboud university medical center

Target group

Master
PhD
Post-doc

This course is designed for Master students, PhD students and postdocs with a biomedical/biochemical background. Participants should have a basic level of biomedical, biochemical and/or chemistry and physics knowledge.

Course aim

After this course you are able to :

- Select the appropriate radionuclide for your application
- Characterize a radiotracer with in vitro methods
- Set up and perform an in vivo PET/SPECT imaging study

Fee info

EUR 600: The fee includes registration fees, course materials, access to library and IT facilities, coffee/tea, lunch, and a number of social activities.

Scholarships

We offer several reduced fees.

Register for this course
on course website